SB 1449 - This act provides that an enrollee's health benefit plan shall not deny coverage of a nonopioid prescription drug in favor of an opioid drug, require the enrollee to try an opioid drug before covering the nonopioid prescription drug, or require a higher level of cost-sharing for a nonopioid prescription drug than for an opioid drug. This act shall apply to health benefit plans delivered, issued for delivery, continued, or renewed in this state on or after January 1, 2027. This act is similar to SCS/SB 841 (2026), SB 902 (2026), HCS/SB 1019 (2026), SB 1350 (2026), SB 158 (2025), HCS/HB 2372 (2026), HCS/HBs 2642, 2296, 1966 & 1680 (2026), HB 804 (2025), and HCS/SS/SB 7 (2025). TAYLOR MIDDLETON

2026 Regular Session

Missouri health plans cannot deny, require trying opioids first, or charge higher cost-sharing for nonopioid prescriptions for acute pain prescribed by a licensed clinician, starti

Second Read and Referred S Insurance and Banking Committee

Summary of SB 1449 (Session: 2026, Missouri)

Purpose and intent

SB 1449 aims to ensure that health benefit plans within Missouri must cover nonopioid prescription medications for acute pain, without forcing a preference for opioids. Specifically, it prohibits plans from denying nonopioid coverage, requiring patients to try an opioid first, or imposing higher cost-sharing for nonopioids when a licensed health care professional prescribes a nonopioid for acute pain.

Key provisions and changes

Scope and applicability: The measure applies to health benefit plans delivered, issued for delivery, continued, or renewed in Missouri on or after January 1, 2027.

Definitions: The bill defines terms used in the section, including “acute pain,” “enrollee,” “health benefit plan,” and “health care professional.”

“Acute pain” is pain resulting from disease, trauma (accidental or intentional), or other causes that a health care provider reasonably expects to last 30 days or fewer.

Prohibition on discrimination against nonopioids for acute pain:

If a licensed health care professional prescribes a nonopioid medication for acute pain, a health benefit plan may not:
Deny coverage of the nonopioid prescription drug in favor of an opioid prescription drug.
Require the enrollee to try an opioid prescription drug before providing coverage for the nonopioid drug.
Require a higher level of cost-sharing for the nonopioid drug than for an opioid drug.

Effective date: The prohibitions and protections take effect for plans delivered, issued, continued, or renewed on or after January 1, 2027.

Who/what is affected

Enrollees: Individuals with health benefit plans subject to Missouri law who are prescribed nonopioid medications for acute pain.

Health benefit plans: Insurance plans regulated under Missouri Chapter 376, including plans delivered or renewed after January 1, 2027.

Health care professionals: Prescribers whose nonopioid prescriptions for acute pain trigger plan protections from denial or higher cost-sharing.

Procedural and timeline aspects

Effective date: January 1, 2027, for all applicable health benefit plans.

Legislative context: SB 1449 is positioned as similar to multiple other 2025–2026 Missouri measures (e.g., SB 841, SB 902, SB 1019, SB 1350, SB 158, and related bills). It was introduced in the 103rd General Assembly and referred to the Senate Insurance and Banking Committee for consideration.

Potential impact and considerations

May increase access to nonopioid treatments for acute pain by preventing plan discrimination in favor of opioids.

Could influence prescription practices by ensuring nonopioids are covered on par with opioids, potentially supporting nonpharmacologic pain management strategies when appropriate.

May reduce patient financial barriers to nonopioid medications by aligning cost-sharing with nonopioids to avoid undue penalty relative to opioids.

Implementation will require plans to review and adjust coverage policies to ensure compliance starting in 2027.

Note: The summary reflects the bill text and stated provisions as introduced; actual implementation may be affected by amendments or regulatory guidance during the legislative process.